MX2024012300A - Terapia de combinación de agonista de receptor 5 de muerte (dr5) e inhibidor de cinasa 1 tipo polo (plk1) o inhibidor de cinasa dependiente de ciclina (cdk) - Google Patents
Terapia de combinación de agonista de receptor 5 de muerte (dr5) e inhibidor de cinasa 1 tipo polo (plk1) o inhibidor de cinasa dependiente de ciclina (cdk)Info
- Publication number
- MX2024012300A MX2024012300A MX2024012300A MX2024012300A MX2024012300A MX 2024012300 A MX2024012300 A MX 2024012300A MX 2024012300 A MX2024012300 A MX 2024012300A MX 2024012300 A MX2024012300 A MX 2024012300A MX 2024012300 A MX2024012300 A MX 2024012300A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- agonist
- combination therapy
- plk1
- cdk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328951P | 2022-04-08 | 2022-04-08 | |
| PCT/US2023/065489 WO2023196943A1 (en) | 2022-04-08 | 2023-04-07 | Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012300A true MX2024012300A (es) | 2025-01-09 |
Family
ID=86272460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012300A MX2024012300A (es) | 2022-04-08 | 2024-10-03 | Terapia de combinación de agonista de receptor 5 de muerte (dr5) e inhibidor de cinasa 1 tipo polo (plk1) o inhibidor de cinasa dependiente de ciclina (cdk) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250215101A1 (https=) |
| EP (1) | EP4504785A1 (https=) |
| JP (1) | JP2025512950A (https=) |
| KR (1) | KR20250004725A (https=) |
| CN (1) | CN119365489A (https=) |
| AU (1) | AU2023248848A1 (https=) |
| CA (1) | CA3247628A1 (https=) |
| IL (1) | IL316085A (https=) |
| MX (1) | MX2024012300A (https=) |
| TW (1) | TW202404636A (https=) |
| WO (1) | WO2023196943A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097179A1 (en) * | 2022-11-02 | 2024-05-10 | Vincerx Pharma, Inc. | Combination therapies comprising a cdk9 inhibitor for cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| WO2003072062A2 (en) | 2002-02-28 | 2003-09-04 | Temple University-Of The Commonwealth System Of Higher Education | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP3876265B2 (ja) | 2003-02-26 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ジヒドロプテリジノン、その製造方法及び薬物形態での使用 |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US7796945B2 (en) | 2006-09-29 | 2010-09-14 | Motorola, Inc. | Method and system for associating devices in a personal area network |
| PL2205603T3 (pl) | 2007-09-28 | 2014-07-31 | Cyclacel Ltd | Pochodne pirymidyny jako inhibitory kinaz białkowych |
| AR076784A1 (es) | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
| CA2991634C (en) * | 2015-07-16 | 2026-03-17 | Inhibrx Biosciences, Inc. | Multivalent and multispecific dr5-binding fusion proteins |
| IL305265A (en) * | 2021-02-19 | 2023-10-01 | Inhibrx Inc | Preparations of DR5-binding polypeptides |
-
2023
- 2023-04-07 AU AU2023248848A patent/AU2023248848A1/en active Pending
- 2023-04-07 WO PCT/US2023/065489 patent/WO2023196943A1/en not_active Ceased
- 2023-04-07 US US18/853,278 patent/US20250215101A1/en active Pending
- 2023-04-07 CN CN202380042671.1A patent/CN119365489A/zh active Pending
- 2023-04-07 TW TW112113053A patent/TW202404636A/zh unknown
- 2023-04-07 KR KR1020247037073A patent/KR20250004725A/ko active Pending
- 2023-04-07 EP EP23720526.5A patent/EP4504785A1/en active Pending
- 2023-04-07 CA CA3247628A patent/CA3247628A1/en active Pending
- 2023-04-07 JP JP2024559130A patent/JP2025512950A/ja active Pending
- 2023-04-07 IL IL316085A patent/IL316085A/en unknown
-
2024
- 2024-10-03 MX MX2024012300A patent/MX2024012300A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119365489A (zh) | 2025-01-24 |
| JP2025512950A (ja) | 2025-04-22 |
| US20250215101A1 (en) | 2025-07-03 |
| EP4504785A1 (en) | 2025-02-12 |
| IL316085A (en) | 2024-12-01 |
| WO2023196943A1 (en) | 2023-10-12 |
| CA3247628A1 (en) | 2023-10-12 |
| TW202404636A (zh) | 2024-02-01 |
| AU2023248848A1 (en) | 2024-10-17 |
| KR20250004725A (ko) | 2025-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025001648A (es) | Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras) | |
| JOP20240223A1 (ar) | معالجات سرطان باستخدام مثبطات prmt5 بالتعاون مع mta | |
| MX2025015502A (es) | Inhibidores del oncogén de sarcoma de rata de kirsten (kras) | |
| EP4085919A3 (en) | Compositions and methods to treat cancer | |
| MX2025001714A (es) | Medicamento para el tratamiento y/o prevencion del cancer | |
| MX2025008674A (es) | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos | |
| MX2024012300A (es) | Terapia de combinación de agonista de receptor 5 de muerte (dr5) e inhibidor de cinasa 1 tipo polo (plk1) o inhibidor de cinasa dependiente de ciclina (cdk) | |
| MX2025007373A (es) | Tratamientos del cancer con inhibidores de prmt5 cooperativos con mta | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2024000674A (es) | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| MX2023005234A (es) | Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b. | |
| WO2024249769A8 (en) | Combination therapy for treating hematological cancers | |
| MX2025011869A (es) | Terapia de combinacion que comprende un inhibidor de parg y un inhibidor de topoisomerasa para tratar cancer | |
| MX2023006542A (es) | Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo. | |
| ZA202406390B (en) | Compounds and their use in treating cancer | |
| EP4335503A3 (en) | Methods of treating or preventing spinal muscular atrophy | |
| MX2024015041A (es) | Fitusiran para el tratamiento de la hemofilia a y b | |
| EP4319729A4 (en) | CANCER TREATMENT WITH PARP INHIBITORS AND PLK1 INHIBITORS | |
| MX2025002424A (es) | Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2025009464A (es) | Debio-0123 en combinacion con temozolomida y radioterapia para uso en el tratamiento del glioma | |
| MX2025002182A (es) | Terapias de combinacion que usan inhibidores de proteina arginina n-metil transferasa 5 (prmt5) e inhibidores de la familia del oncogen de linfoma de celulas b 2 (bcl-2) para el tratamiento del cancer | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. |